(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial
Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010....
View Article(ENZN) Enzon Pharma Announces European Approval for Cimzia
Yesterday, Enzon Pharma (ENZN) announced the European Commission approval of UCB’s Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis...
View Article(ENZN) Enzon Beats Expectations – Announces Sell-off
Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported...
View Article(ENZN) Enzon Pharmaceuticals Analyst Cuts Shares to Underperform
We are downgrading Enzon Pharmaceuticals (ENZN) to Underperform from Neutral because of concerns regarding the disappointing third quarter results, declining royalty revenues, the principal source of...
View Article(ENZN) Enzon Pharmaceuticals Analyst Holds Shares at Neutral
We have maintained our Neutral recommendation on Enzon Pharmaceuticals, Inc. (ENZN) with a target price of $12.00 after announcement of fourth quarter and full year 2010 results. Enzon Pharmaceuticals’...
View Article(SONS) ValuEngine Weekly News
MARKET OVERVIEW Index started week Thursday Close 4 day change 4 day change % ytd DJIA 12339.71 12506 166.29 1.35% 8.02% NASDAQ 2731.22 2820.16 88.94 3.26% 6.31% RUSSELL 2000 826.99 845.64 18.65 2.26%...
View Article(ENZN) Enzon Pharmaceuticals – Bear of the Day
Enzon Pharma’s (ENZN) first quarter 2011 net loss of $0.07 per share was narrower than the year-ago loss of $0.20 due to substantial cost cutting by management. The discontinuation of the development...
View Article(ENZN) Enzon Pharmaceuticals – Bear of the Day
Enzon Pharma’s (ENZN) first quarter 2011 net loss of $0.07 per share was narrower than the year-ago loss of $0.20 due to substantial cost cutting by management. The discontinuation of the development...
View Article(ENZN) Enzon Pharmaceuticals’ Weak Top Line Widens Loss
Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in...
View Article(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell
We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its...
View Article(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut
Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development...
View Article
